1 The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsA Long-Term Evaluation), a large double-blind, placebo-controlled trial, recently demonstrated that liraglutide added to standard therapy for a relatively short period of time (3.5-5 years) had a significant reduction in cardiovas-cular events and mortality compared to placebo in high-risk patients (hazard ratio [HR], 0.87
With the right combination of at-home care and advanced treatments, you can look as good as you feel
Haines noted that it is still unclear which patients are most likely to lose muscle and how this muscle loss might impact blood sugar control
Good candidates for using semaglutide typically include Adults who are overweight or obese and have struggled to lose weight through diet and exercise alone
The rate of loss may plateau temporarily as your body adjusts, which is a normal physiologic response requiring patience rather than dose escalation
Key Takeaways: Ozempic generally lowers A1C more effectively than Jardiance